Michael D Briggs Selected Research

Osteochondrodysplasias (Spondyloepiphyseal Dysplasia)

1/2019	XBP1 signalling is essential for alleviating mutant protein aggregation in ER-stress related skeletal disease.
1/2015	Increased classical endoplasmic reticulum stress is sufficient to reduce chondrocyte proliferation rate in the growth plate and decrease bone growth.
12/2013	Armet/Manf and Creld2 are components of a specialized ER stress response provoked by inappropriate formation of disulphide bonds: implications for genetic skeletal diseases.
8/2013	Analysis of the cartilage proteome from three different mouse models of genetic skeletal diseases reveals common and discrete disease signatures.
1/2013	Mild myopathy is associated with COMP but not MATN3 mutations in mouse models of genetic skeletal diseases.
5/2012	Loss of matrilin 1 does not exacerbate the skeletal phenotype in a mouse model of multiple epiphyseal dysplasia caused by a Matn3 V194D mutation.
1/2012	A novel form of chondrocyte stress is triggered by a COMP mutation causing pseudoachondroplasia.
11/2010	An unfolded protein response is the initial cellular response to the expression of mutant matrilin-3 in a mouse model of multiple epiphyseal dysplasia.
4/2010	Type IX collagen gene mutations can result in multiple epiphyseal dysplasia that is associated with osteochondritis dissecans and a mild myopathy.
11/2007	Structural and functional characterization of recombinant matrilin-3 A-domain and implications for human genetic bone diseases.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael D Briggs Research Topics

Disease

14	Osteochondrodysplasias (Spondyloepiphyseal Dysplasia) 01/2019 - 06/2005
12	Pseudoachondroplasia 01/2015 - 05/2002
6	Osteoarthritis 01/2014 - 07/2007
5	Dwarfism 10/2017 - 07/2007
2	Muscular Diseases (Myopathy) 04/2010 - 01/2010
1	Seizures (Absence Seizure) 10/2017
1	Disease Progression 10/2015
1	Joint Instability (Joint Laxity) 12/2011
1	Osteochondritis Dissecans 04/2010
1	Aggrecan Type Spondyloepimetaphyseal Dysplasia 01/2009
1	Bone Diseases (Bone Disease) 11/2007

Drug/Important Bio-Agent (IBA)

11	Matrilin ProteinsIBA 01/2019 - 05/2002
11	Cartilage Oligomeric Matrix ProteinIBA 01/2015 - 05/2002
4	Proteins (Proteins, Gene)FDA Link 01/2019 - 11/2010
4	CollagenIBA 10/2017 - 01/2010
3	Collagen Type IXIBA 01/2012 - 05/2002
2	Collagen Type XIBA 10/2017 - 10/2009
1	Pharmaceutical PreparationsIBA 10/2017
1	Mutant Proteins (Protein, Mutant)IBA 10/2017
1	Carbamazepine (Tegretol)FDA LinkGeneric 10/2017
1	Biomarkers (Surrogate Marker)IBA 10/2015
1	KinesinsIBA 12/2011
1	Glycoproteins (Glycoprotein)IBA 01/2010
1	Creatine Kinase (Creatine Phosphokinase)IBA 01/2010
1	Aggrecans (Aggrecan)IBA 01/2009
1	C-Type Lectins (C-Type Lectin)IBA 01/2009